Grzegorz Nowakowski, MD, and Koen Van Besien, MD, PhD, debated the best therapy for the treatment of a young patient with recurrent follicular lymphoma and a short first remission.

Accredited CME from Imedex

Robert Z Orlowski, MD, PhD, outlines the key take-home messages from the session on plasma cell disorders by first outlining the most current evidence-based data for initial, maintenance, and refractory/relapsed therapy.
David P Steensma, MD outlines the key take-home messages from the leukemia, benign hematology, and myeloid disorders sessions by providing an overview of new and emerging evidence-based data for CLL, non-malignant hematology, CML, ALL, MDS, and MPN.
John P Leonard, MD, outlines the key take-home messages from the lymphoma session by providing an overview of evidence-based data pertinent to practicing clinicians in the therapeutic area of lymphoma.

Conferences

On April 13th and 14th, 2018, meeting co-chairs John Leonard, MD, and David Steensma, MD, will join other nationally-recognized leaders to explain the latest updates in the hematologic malignancies space and take opposing sides on topics of clinical interest.
Clinicians are now trying to treat multiple myeloma similar to leukemia, according to George Somlo, MD, who discussed treatment regimens at the 2016 NCCN Annual Congress on Hematologic Malignancies.
Since 2015, the US Food and Drug Administration has approved 4 new therapies for the treatment of multiple myeloma: panobinostat, daratumumab, ixazomib, and elotuzumab.
Autologous stem cell transplantation is still the preferred treatment of choice for patients under the age of 65 years with newly diagnosed multiple myeloma.

Features

Welcome to Oncology Newswatch's case report exploration. This interactive case report will engage your experience and knowledge about details of a given case. Along the way, we will provide details and at the end, we will share the patient's outcome.
Welcome to Journal of Clinical Pathway’s case report exploration. This interactive case report will engage your experience and knowledge about the details of a given case. Along the way, we will provide details and at the end, we will share the patient’s outcome.

News

Progression-free survival in patients with chronic myeloid leukemia with a major molecular response may be predicted 2.5 years after diagnosis.
The National Comprehensive Cancer Network treatment guidelines for multiple myeloma still promote the use of supportive care as a critical component of care.
The US Food and Drug Administration has granted approval for a drug to include treatment of first- and second-line pediatric patients with chronic myeloid leukemia.
Patients with multiple myeloma may not be receiving optimal therapy for bone disease.

Quiz

According to a recent study, maintenance therapy with which agent prolongs time to remission after autologous stem cell transplantation in multiple myeloma?
According to recent research presented at ASCO, adding which targeting agent to standard of care carfilzomib, lenalidomide, and dexamethasone is a safe and efficacious alternative to ASCT for patients with multiple myeloma?

Research in Review

Targeted therapy against a particular protein has the potential to improve outcomes and fracture-free survival for patients with multiple myeloma.
Adult patients with multiple myeloma who receive a high-dose chemotherapy regimen plus autologous stem-cell transplantation improve their median PFS by 14 months compared with patients who receive chemotherapy alone.
Single agent daratumumab may serve as a more cost-effective treatment strategy than pomalidomide for patients with refractory multiple myeloma.
A triple-combination treatment strategy is the most effective therapy for patients with relapsed or refractory multiple myeloma.
Subscribe to Hematologic Malignancies